BCDA Stock Discussion

BioCardia, Inc. Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Bone Stem Cell Cell Therapy Catheter Cardiovascular Disease Heart Failure Vascular Disease Regenerative Medicine Heart Disease Aging Associated Diseases Vascular Access Products Bone Marrow Ischemia Treatment Of Heart Failure